Business Context and Reporting Period
Corbus Pharmaceuticals Holdings, Inc., an emerging growth company, filed this Form 8-K on November 7, 2019. The filing serves to disclose financial information and operating metrics for the fiscal quarter ended September 30, 2019, via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that these details are contained within the attached press release (Exhibit 99.1) and are not presented directly in the body of this Form 8-K.
Material Changes
The filing does not provide specific data regarding material changes versus the prior comparable period. It references the attached press release for the discussion of operating metrics and financial results for the quarter ended September 30, 2019.
Guidance, Outlook, and Risks
Management discussed the company's business outlook in the press release referenced in Item 2.02. The filing notes that the information provided under Items 2.02 and 7.01 is furnished under Regulation FD and is not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 7, 2019) for specific revenue, cash burn, and liquidity figures.
- Verify the specific operating metrics and clinical trial updates mentioned in the referenced press release.
- Confirm the company's status as an emerging growth company and its election regarding the extended transition period for new accounting standards.
- Note that the financial data in this 8-K is not legally "filed" under Section 18 of the Exchange Act, limiting liability exposure for the forward-looking statements contained therein.